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The method here presented is an alternative for the production of recombinant hemoglobin in Saccharomyces cerevisiae. This process  allows us to generate hemoglobin with a very 
high purity (99.98%) which could be used for blood transfusions in the future once it is encapsulated in liposomes. However, the purifying steps could be improved since there are many 
losses of hemoglobin during the process.  
The main goal of this project is to build an industrial production plant of hemoglobin which could be used as a replacement for blood transfusions in a 
close future. This way, we would completely end with the donation-dependent actual system and the transfusions would become much easier. In this part 
of the project we treat the plant design aspects: first of all, how to produce the microorganism previously designed, in this case, Saccharomyces cerevisiae, 
then how to synthesize the hemoglobin with this microorganism and last of all, how to separate and purify hemoglobin. 
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 Getting a big amount of 
biomass in order to produce 
the hemoglobin is the first 
important part of the process. 
To do so, we use a number of 
discontinuous batches in 
which we grow 
Saccharomyces. The volume 
of the reactors will become 
greater in each step until we 
get to 1000m3. To achieve this, 
we use glucose as a substrate 
for the growth, which allows 
us to get the greatest growth 
rate possible. 
  Once we have the necessary 
amount of biomass, we will 
induce the hemoglobin 
production in the same last 
bioreactor1. Later, the 
hemoglobin will be purified 
following first of all, volume 
reduction steps like  
centrifugation and 
microfiltration, and then 
purifying steps (mainly 
chromatographies). After all 
these phases, we obtain 
hemoglobin  as a product 
made following GMP. 
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Figure 1. SuperPro Designer simulation. 
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S. cerevisiae has a typical growth curve when it is cultured, with 3 phases: lag, exponential growth and stationary phase. We use yeast in exponential phase in order to 
inoculate each reactor. In presence of medium with all of the necessary compounds and glucose as a substrate, the biomass keeps increasing in every step. However, 
during the growth, S. cerevisiae produces ethanol has a by-product that can inhibit the growing process. The concentration of this by-product should, then, be controlled. 
HeŵoglobiŶ’s production in the modified yeast is under the control of the promoter of the lac operon so we need to add lactose so that the product is generated. Once 
the biomass has grown , the medium containing the remaining glucose will be removed from the reactor. Then, new medium containing lactose will be added. It is then 
that the stationary phase can begin and the heŵoglobiŶ’s production will be induced due to the lac-operon control. Later, we will need to purify this product. 
During the process of the bioreaction there are 
several variables that need to be controlled in 
order to get the best growth rate for S. 
cerevisiae. The temperature, pH, pO2, and OD 
are critical for the reaction. The process has 
been designed based in the Quality by Design 
method. This allows us to watch over each 
variable almost in real time and correct possible 
risks before it is too late for the product. This 
can be done due to the actual PAT technologies. 
The fact that the hemoglobin produced isŶ’t secreted to 
the extracellular medium is an advantage. This allows us 
to reduce the volume of the solution easily, since the 
hemoglobin is protected in the intracellular 
environment. However, the product needs to be 
separated from the rest of the cellular compounds and 
the first step is breaking the cellular membrane using a 
mechanical method of disruption, in this case, a bead 
milling. It consists on a cylinder with balls of different 
sizes –beads– that move when the rotor spins and 
impact against the cells breaking their membranes. 
Several steps of purification are performed to 
obtain GMP qualified hemoglobin. However, the 
most important is the chromatography. There are 
three of them in this process (two of them based in 
anionic exchange and one of them based in 
hydrophobic interaction). These chromatographies 
use the particular hemoglobin properties in order to 
differentiate it from the rest of the proteins in the 
cell and separate it2. 
Figure 1. Evolution of the principle compounds of the reaction. 
Process design is carried out simulating all the variables in the program SuperPro Designer. This helps us to get a realistic process without necessary experimental results. 
DESIGN 
BIBLIOGRAPHY 
